M801

antibody from Invitrogen Antibodies

Targeting: CXCL8 3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1

Western blot

ELISA

Antibody data

Submit

Validation data

CXCL8 protein structure - M801 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Sandwich ELISA analysis of human IL-8 was performed using a Human IL-8 Colorimetric ELISA kit (Product # EH2IL8) by loading 50 µL per well of Human IL-8 Recombinant Protein (Product # SIL8) in dodecuplicate at 1000, 400, 160, 64, 25.6, and 0 pg/mL across a 3 µg/mL mouse anti-Human IL-8 (Product # M801) pre-coated plate and incubating for 1 hour at room temperature. The plate was washed, and then incubated with 50 µL per well of a biotinylated mouse anti-human IL-8 monoclonal antibody (Product # M802B) in duplicate at 0.25 µg/mL for 1 hour at room temperature. The plate was washed and incubated with 100 µL per well of Streptavidin-HRP (Product # N504) in all test wells at a 1:4,000 dilution for 30 minutes at room temperature. Detection was performed using 1-Step Ultra TMB substrate (Product # 34028) for 30 minutes at room temperature in the dark. The plate was then stopped with 0.16M sulfuric acid. Absorbances were read on a spectrophotometer at 450-550 nm.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Microparticle composition influences inflammatory cytokine production from activated monocytes. THP-1 cells ( A ) or CD14 sorted blood monocytes ( B ) were treated with control microparticles (grey bars) or PPARgamma-overexpressing microparticles (black bars) or no microparticles (white bars) for 4 hours before activation with LPS or PAM3CSK4 for 24 hours. Supernatants were collected and pro-inflammatory cytokines IL-8 (top), MCP-1 (bottom) were measured by ELISA. Dotted line represents baseline cytokine production from unactivated cells with no microparticle exposure. Mean values with standard errors represent one of at least 3 experiments. Two-way ANOVA with Tukey's multiple comparison post test was performed to determine statistical significance. * indicates (p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 Co-expression of progerin with Bodipy and IL-8 in HGPS differentiated SKPs. ( a ) Immunofluorescence staining for progerin and Bodipy at days 7 and 14 of adipogenesis in HGPS (HGADFN127). ( b ) Immunofluorescence staining for progerin and IL-8 at days 7 and 14 of adipogenesis in HGPS. Cells were counterstained with DAPI. ( c ) Percentage of positive nuclei expressing either progerin, Bodipy, or both (progerin/Bodipy 493/503). ( d ) Percentage of progerin-positive nuclei, IL-8-positive or progerin/IL-8-positive cells. Values are presented as mean +- SD ( n = 3), not significant (ns), ** p < 0.01, ( c , d ) unpaired t -test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 2 FIGURE CAFs up-regulated NRP-1 expression by IL-8 in gallbladder cancer (GBC). (A) CAFs up-regulated NRP-1 expression in different GBC cell lines (GBC-SD, SGC-996 and NOZ). (B) Cytokine array cluster analysis of the exocrine cytokines in CAFs and NFs. (C) The IL-8 expression in CAFs and NFs were determined by ELISA Kit. (D) IL-8 in NFs and CAFs cells. Green: IL-8 (marked with arrow); Blue: nuclei (stained with DAPI). Scale bar: 25 mum. (E) IL-8 up-regulated NRP-1 expression in different GBC cell lines (GBC-SD, SGC-996 and NOZ). (F) IL-8 receptors inhibitor Reparixin reduced the expression of NRP-1 in GBC cell lines which up-regulated by CAFs supernatants (GBC-SD, NOZ). * P < .05 by ANOVA